196 results about "Pain chronic" patented technology

The present invention relates to novel drug depot implant designs for optimal delivery of therapeutic agents to subjects. The invention provides a method for alleviating pain associated with neuromuscular or skeletal injury or inflammation by targeted delivery of one or more therapeutic agents to inhibit the inflammatory response which ultimately causes acute or chronic pain. Controlled and directed delivery can be provided by drug depot implants, comprising therapeutic agents, specifically designed to deliver the therapeutic agent to the desired location by facilitating their implantation, minimizing their migration from the desired tissue location, and without disrupting normal joint and soft tissue movement.

The present invention relates to methods of affecting chronic pain by electrically and / or chemically stimulating target sites of the pain circuitry associated with chronic pain. Such target sites include cerebral target sites, including limbic structures, associated with the emotional and suffering components of chronic pain, as well as deep brain target sites associated with the affective and sensory components of chronic pain. Also provided is a method of affecting chronic pain by stimulating a target site of the pain circuitry associated with chronic pain to stimulate the synthesis or release of endogenous opioids.

A method of eliciting analgesia in a human subject by Transcranial Electrical Stimulation (TCES, herein “TES”) is provided. Electrodes secured to the skin of the subject's head at particular sites provide an electrical current that includes a direct current combined with rectangular AC current pulses delivered at a particular frequency of between 10 and 100 Hz. In an embodiment the total current transmitted, a sum of the DC component and a Mean Absolute Deviation (MAD) of the current pulses, has a value between 0.2 and 20 mA. The method is used to produce analgesia during perioperative period, surgery and the post-operative procedure. It can also be used for treating acute chronic pain and a wide variety of other conditions.

Mobile systems and devices can employ surface electromyography (sEMG) technology and other sensing technologies for measuring muscle tension and managing chronic pain conditions. These systems and devices can sense and quantify excessive muscle tension and can facilitate management of excessive muscle tension and chronic pain through cognitive behavioral therapy, pharmacologic intervention, or a combination of both.

The present invention provides a method for the long-term relief of chronic pain in a subject by activating in the subject an analgesic alpha-adrenergic receptor in the absence of alpha-2A receptor activation over a period of at least three days, such that relief of chronic pain is maintained in the absence of continued activation of said receptor. The analgesic alpha-adrenergic receptor can be, for example, the alpha-2B receptor.

Novel and highly stable injectable pharmaceutical compositions comprising at least one cyclooxygenase-II enzyme (COX-II) inhibitor or non-steroidal anti-inflammatory drug (NSAID) or COX / LOX inhibitor, or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs or salts thereof as active ingredient suitable for parenteral administration preferably by intramuscular (IM) or intravenous (IV) route; process of preparing such compositions and therapeutic methods of using such compositions are provided. The analgesic and anti-inflammatory injectable compositions of the present invention are very useful in mammals particularly in humans for the treatment of acute painful conditions like one or more of post-operative trauma, pain associated with cancer, sports injuries, migraine headache, neurological pain and pain associated with sciatica and spondylitis, and the like, and / or chronic painful conditions, and / or a variety of painful and inflammatory conditions like postoperative pain, primary dysmenorrhea and painful osteoarthritis, and / or other associated disorders such as inflammation, fever, allergy, or the like.

The invention relates to BCAT inhibitors and the use thereof for treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the overstimulation of the excitatory amino acids, treating anxiety, psychosis, convulsions, aminoglycoside antibiotics-induced hearing loss, migraine headache, chronic pain, neuropathic pain, Parkinson's disease, diabetic retinopathy, glaucoma, CMV retinitis, urinary incontinence, opioid tolerance or withdrawal, and inducing anesthesia, as well as for enhancing cognition.

The invention is directed to indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis and cancer. Pharmaceutical compositions and methods of use are also included.

The disclosure provides pharmaceutical preparations containing (2R,6R)-hydroxynorketamine, or (R)- or (S)-dehydronorketamine, or other stereoisomeric dehydro or hydroxylated ketamine metabolite. (2R,6R)-hydroxynorketamine The disclosure also provides novel ketamine metabolite prodrugs. The disclosure provides methods of treating, bipolar depression, major depressive disorder, neuropathic and chronic pain, including complex regional pain disorder (CRPS) by administering a purified ketamine metabolite or a ketamine metabolite prodrug directly to patients in need of such treatment.

The invention discloses stem cells for specifically expressing a programmed death receptor 1 (PD-1), and particularly relates to the stem cells from an organic cavity. The stem cells comprise but notlimited to dental pulp stem cells, gingival mesenchymal steam cells (GMSCs), periodontal ligament stem cells (PDLSCs), stem cells of apical papilla (SCAPs) and dental follicle stem cells (DFSCs) or any combination thereof, and preferably comprise stem cells from human exfoliated deciduous teeth (SHED) and / or dental pulp mesenchymal stem cells for permanent teeth (DPSC); the stem cells also includemesenchymal stem cells from other tissues, which do not express the PD-1 at first and express the PD-1 after being modified by CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats), suchas PD-1 plus bone mesenchymal stem cells (BMMSC) modified by the CRISPR. The invention further discloses an identifying and separating method for the stem cells for specifically expressing the PD-1,a method for preparing the PD-1 plus mesenchymal stem cells modified by the CRISPR as well as application of the mesenchymal stem cells for expressing the PD-1, disclosed by the invention, in tissue regeneration, pain relief and treatment of chronic pain and a series of diseases.

The present invention is related to oxindole derivatives of structure (I), compositions containing the same, and methods of use and manufacture of the same. Such compounds generally are useful pharmacologically as agents in those disease states alleviated by the alteration of mitogen activated signaling pathways in general, and in particular in the inhibition or antagonism of protein kinases, which pathologically involve aberrant cellular proliferation. Such disease states include tumor growth, restenosis, atherosclerosis, pain and thrombosis. In particular, the present invention relates to a series of substituted oxindole compounds, which exhibit Trk family protein tyrosine kinase inhibition, and which are useful in cancer therapy and chronic pain indications.

The present invention relates to an analgesic tramadol hydrochloride oral disintegrant tablet. It is made up by using main medicine tramadol hydrochloride and auxiliary material gelatin and / or mannitol and / or aspartame and / or glucose and / or microcrystal cellulose and / or crosslinked povidone and essence, etc. and adopting freeze-drying or coating, granulating and pressing processes. When it is taken in, it has no need of drinking water, it can be quickly disintegrated in oral cavity, and can be used for curing acute and chronic pain, moderate and light pain due to cancer, pain due to fracture and pain after various operations and toothache, and can obtain good therapeutic effect.

The invention relates to BCAT inhibitors and the use thereof for treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the overstimulation of the excitatory amino acids, treating anxiety, psychosis, convulsions, aminoglycoside antibiotics-induced hearing loss, migraine headache, chronic pain, neuropathic pain, Parkinson's disease, diabetic retinopathy, glaucoma, CMV retinitis, urinary incontinence, opioid tolerance or withdrawal, and inducing anesthesia, as well as for enhancing cognition.

The invention discloses an application of a miRNA-219 (micro-ribonucleic acid) compound to preparation of a marker for clinically diagnosing chronic pain disease and a medicament for treating chronic pain. After screening a large number of experiments, an experimental result shows that expression of miRNA-219 in blood of a chronic pain patient is regulated down, generation and formation of the chronic pain can be obviously restrained by regulating the miRNA-219 up, and quantitative analysis is further carried out on a clinical blood specimen of the chronic pain patient to show that the miRNA-219 can be used as the marker of generation of the chronic pain.

The invention relates to cyclic peptide agonists that bind to the mu (morphine) opioid receptor and their use in the treatment of acute and / or chronic pain. Embodiments of the invention are directed to cyclic pentapeptide and hexapeptide analogs of endomorphin that have (i) a carboxy-terminal extension with an amidated hydrophilic amino acid and (ii) a substitution in amino acid position 2. These peptide analogs exhibit decreased tolerance relative to morphine, increased solubility compared to similar tetrapeptide analogs, while maintaining favorable or improved therapeutic ratios of analgesia to side effects.

The present invention is directed to a compound of Formula Ior a pharmaceutically acceptable salt thereof; wherein R, R1, R2, R3, R4, m, and n are as defined herein, to pharmaceutical compositions comprising said compound, and to methods of treating diseases or conditions mediated by elevated persistent sodium current, such as an ocular disorder, multiple sclerosis, seizure disorder, and chronic pain.

The present invention composition features pharmaceutically acceptable salts of psilocin and compositions thereof. The pharmaceutically acceptable salts of psilocin may be used to treat a disease or condition, such as a neurological injury, an inflammatory condition, chronic pain, or a psychological condition, in a subject in need thereof.

The invention discloses cathepsin S as a suitable target for the development of new therapeutics to treat or ameliorate chronic pain. The invention relates to methods to treat and / or ameliorate chronic pain and pharmaceutical compositions therefor comprising modulators with inhibitory effect on cathepsin S enzyme activity and / or cathepsin S gene expression. The invention also relates to a method to identify compounds with therapeutic usefulness to treat chronic pain, comprising identifying compounds that can inhibit cathepsin S activity and / or gene expression which can also reverse the pathological effects of chronic pain in vivo.

The invention discloses an application of lncRNA (long non-coding ribonucleic acid) XR595534.2 in preparation of a medicine for treating or preventing chronic pain. According to the invention, trigeminal neuralgia induced by rat suborbital nerve chronic compression injury is taken as a pain model, a long-chain non-coding RNA gene lncRNA XR595534.2 with high specificity and difference expression in the model is obtained by screening, and interfering RNA for treating diseases taking lncRNA XR59534.2 as a target point is provided. The lncRNA XR595534.2 highly expressed in specificity and difference in a pain model is discovered for the first time, expression of the lncRNA XR59534.2 can be remarkably reduced by positioning injection of interfering RNA, pain behavior reaction is relieved, and the lncRNA XR595534.2 can be used for preparing medicines for preventing or treating prosopalgia, neuropathic pain, migraine and cancer pain.

Compounds, compositions and methods are provided which are useful in the treatment of diseases through the inhibition of sodium ion flux through voltage-dependent sodium channels. More particularly, the invention provides substituted piperidines, and compositions containing these compounds. Also provided are methods using the compounds of the invention for the treatment of central or peripheral nervous system disorders, particularly pain and chronic pain by blocking sodium channels associated with the onset or recurrance of the indicated conditions. The compounds, compositions and methods of the present invention are of particular use for treating neuropathic or inflammatory pain by the inhibition of ion flux through a channel that includes a PN3 subunit.

The invention is directed to the use of at least one CBx modulator wherein the CBx modulator is selected from the group consisting of CB1 agonists; CB2 agonists; CB2 partial agonists; CB2 antagonists; CB2 inverse agonists; and dually acting compounds which are both a CB1 agonist and a CB2 agonist; and mixtures thereof, as KATP channel modulator for the prophylaxis, treatment, delayed progression, delayed onset and / or inhibition of a variety of disease conditions including obesity, diabetes mellitus, metabolic syndrome, syndrome X, insulinoma, familial hyperinsulemic hypoglycemia, male pattern baldness, detrusor hyperreactivity, asthma, neuroprotection, epilepsy, analgesia, cardioprotection, angina, cardioplegia, arrhythmia, coronary spasm, peripheral vascular disease, cerebral vasospasm, appetite regulation, neurodegeneration, pain - including neuropathic pain and chronic pain - and impotence in mammals and humans. The invention further relates to methods of treating, preventing, delaying progression of, delaying onset of and / or inhibiting a variety of disease conditions including obesity, diabetes mellitus, metabolic syndrome, syndrome X, insulinoma, familial hyperinsulemic hypoglycemia, male pattern baldness, detrusor hyperreactivity, asthma, neuroprotection, epilepsy, analgesia, cardioprotection, angina, cardioplegia, arrhythmia, coronary spasm, peripheral vascular disease, cerebral vasospasm, appetite regulation, neurodegeneration, pain - including neuropathic pain and chronic pain - and impotence in mammals and humans comprising administering to a subject in need thereof an effective amount of at least one CBx modulator having KATP channel modulating properties.

The present invention is directed to methods and assays for identifying subjects participating in clinical trials that may exhibit a placebo response and identifying treatments for subjects with varying degrees of placebo responses. In one aspect, a method of selecting subjects to participate in a clinical trial is disclosed. In another aspect, methods for treating a subject and determining a treatment dosage are disclosed. In an exemplary embodiment, a method for determining a response to a treatment of a subject having, suspected of having, or at risk for developing a disorder, such as cardiovascular disorder, irritable bowel syndrome, diabetes, autoimmune disorders, inflammation, neurological disorders, chronic pain, cancer, cancer treatments, allergies, depression, migraines, addiction, obesity, and other disorders, syndromes, or diseases, is disclosed.

Chronic pain is alleviated in a mammal suffering there from by administering to the mammal a chronic pain alleviating amount of a nontoxic N-methyl-D-aspartate receptor antagonist such as dextromethorphan, dextrorphan, ketamine or pharmaceutically acceptable salt thereof, in combination with a μ-opiate analgesic such as tramadol or an analogously acting molecular entity, and a methylxanthine such as caffeine, and optionally in sustained release dosage form.

This invention relates to tetrahydro-naphthalene derivatives and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The tetrahydro-naphthalene derivatives of the present invention have an excellent activity as VR1 antagonist and useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, incontinence, inflammatory disorders such as asthma and COPD.